Achilles Therapeutics plc

General Information

We are a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. We are focused on advancing cancer therapies through our pioneering work in the field of tumor evolution and our belief that clonal neoantigens represent the most specific class of cancer cell targets. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient’s cancer cells but are absent from healthy tissue. We refer to this novel class of solid tumor targets as clonal neoantigens.

To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the unique tumor genetic data derived from our exclusive license to data from the TRACERx study, which aims to analyze tumor samples from more than 840 non-small cell lung cancer, or NSCLC, patients. Once we have identified the clonal neoantigens, our proprietary manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a Clonal Neoantigen Targeting T cell therapy, or cNeT, that specifically targets multiple clonal neoantigens to eradicate the tumor. We are currently conducting two open-label Phase I/IIa trials to evaluate our cNeT product candidate, ATL001, in advanced NSCLC and metastatic or recurrent melanoma; we expect to report interim data from these trials in the second half of 2022.

(Note: Achilles Therapeutics priced its IPO on March 30, 2021, at $18 – the mid-point of its $17-to-$19 range – on 9.75 million shares to raise $175.5 million.)



Employees: 153
Founded: 2016
Contact Information
Address 245 Hammersmith Road London W6 8PW United Kingdom
Phone Number +44 (0)20 8154 4600
Web Address
View Prospectus: Achilles Therapeutics plc
Financial Information
Market Cap $731.16mil
Revenues $0 mil (last 12 months)
Net Income $-33.2 mil (last 12 months)
IPO Profile
Symbol ACHL
Exchange NASDAQ
Shares (millions): 9.8
Price range $18.00 - $18.00
Est. $ Volume $175.5 mil
Manager / Joint Managers J.P. Morgan/ BofA Securities/ Piper Sandler/ Chardan/ Oppenheimer & Co./ Kempen & Co.
CO-Managers -
Expected To Trade: 3/31/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change